---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-036589"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:01:51.813370+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics reports net loss of $22.8M in H1 2024; cash $93.4M; AVTX-009 Phase 2 enrollment on track for H2

## Summary
- Cash and cash equivalents $93.4M as of June 30, 2024; expected cash runway into 2027.
- Net loss for six months ended June 30, 2024 was $22.8M, compared to $18.1M in same period 2023.
- AVTX-009 IND for hidradenitis suppurativa active; Phase 2 LOTUS Trial first patient enrollment expected H2 2024.
- Appointed Dr. Mittie Doyle as CMO and Paul Varki as CLO; Q2 2024 net income of $98.5M from warrant liability fair value change.

## SEC filing metadata
- accession: 0001628280-24-036589
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024036589/0001628280-24-036589-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024036589/avtx-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-036589
- JSON: https://secwatch.observer/filing/0001628280-24-036589.json
- Plain text: https://secwatch.observer/filing/0001628280-24-036589.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.